What did @garybreckaofficial actually say?
Brecka claims these "PEPTUAL patches" use a microchip with a small battery to push peptides like glutathione, BPC-157, NAD+, and GHK-Cu through your skin and "right into the bloodstream" over 12 to 14 hours. He frames this as a needle-free alternative to injections and IV drips, calling it "a really cool technology." That last part, at least, is doing a lot of heavy lifting.
To be fair, he is describing something real: iontophoresis, a technique where a low electrical current drives charged molecules across the skin barrier. It is used clinically for localized drug delivery, including lidocaine and certain anti-inflammatories. So the device concept is not science fiction. The problem is everything he implies about what gets delivered, and where it ends up.
Does the science back this up?
On transdermal peptide delivery specifically, the evidence is thin and the biology is not cooperative. The short answer is: small molecules can sometimes cross skin barriers, large peptides basically cannot at meaningful concentrations.
Skin is designed to keep things out. The stratum corneum is an effective barrier against molecules above roughly 500 daltons. Glutathione clocks in around 307 daltons, which puts it in a borderline range. Some research suggests topical glutathione precursors can influence skin oxidative status locally (Weschawalit et al., 2017, Clinical, Cosmetic and Investigational Dermatology), but systemic elevation through transdermal application has not been convincingly demonstrated in humans.
BPC-157 is a 15-amino acid peptide with a molecular weight around 1,419 daltons. NAD+ sits around 663 daltons. GHK-Cu is smaller at roughly 340 daltons and has the most plausible case for some transdermal absorption. But "some absorption" and "dispenses the peptide right into the bloodstream" are not the same claim. Iontophoresis can improve delivery of small charged molecules, but getting intact, bioavailable peptides of this size through intact human skin at therapeutically relevant concentrations has not been established in peer-reviewed literature for these specific compounds.
What did they get wrong (or right)?
Brecka gets the device mechanism partially right and the biology significantly wrong. Credit where it is due: iontophoresis is a real delivery method, not pseudoscience on its face. GHK-Cu has the most legitimate transdermal research behind it and is used in cosmetic formulations with some supporting evidence for local tissue effects (Pickart et al., 2015, Journal of Aging Science).
Where this falls apart is the claim that these patches deliver peptides "right into the bloodstream." That is a systemic absorption claim, and for BPC-157 and NAD+ at their molecular weights, no published human data supports it via patch delivery. BPC-157 research showing healing effects uses injectable or oral routes (Sikiric et al., 2018, Current Pharmaceutical Design). NAD+ precursors like NMN and NR have oral absorption data, but transdermal NAD+ delivery at clinically relevant levels is not established.
Calling this "no injections, just science" while making systemic bioavailability claims is the kind of marketing language that should make anyone pause. The science does not yet confirm the core promise being sold here.
What should you actually know?
If you are considering these patches because you want the benefits attributed to BPC-157 or NAD+, there are a few things worth knowing before you spend money on the premise that a patch is equivalent to an injection or IV infusion.
- Transdermal drug delivery is real and FDA-approved for specific small molecules, including nicotine, fentanyl, and estradiol. These work because of specific molecular properties and formulation science developed through clinical trials.
- Peptides are generally fragile. They can be degraded by enzymes in the skin before reaching systemic circulation, even if they cross the stratum corneum.
- No peer-reviewed clinical trial has demonstrated that a transdermal BPC-157 patch produces measurable plasma levels of intact BPC-157 in humans. If that data exists, it has not been published in an accessible journal.
- GHK-Cu is the one peptide here with the most reasonable transdermal case, and its effects at that level appear to be primarily local, not systemic.
- The FDA has not approved any of these peptides in patch form. If you are looking for peptide therapy, talk to a licensed provider who can discuss routes of administration backed by actual pharmacokinetic data.
The technology sounds compelling. The marketing is ahead of the evidence.